APLN and cancer: The differences related to insulin sensitivity in cancer patients with or without cachexia might rely on degree of peripheral resistance as additional mechanisms in cancer cachexia, such as adipose tissue alterations and hormonal deregulations (glucagon, GLP-1, ghrelin, vitamin D, testosterone, apelin), in turn enforce it (Bartlett, Charland and Torosian, 1995; Burney et al., 2012; Guillory, 2013; Borner et al., 2018; Dev, Bruera and Dalal, 2018; Cecconi et al., 2022).